- Home
- CION vs AUTL Comparison
CION vs AUTL Comparison
Compare CION & AUTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CION | AUTL |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 496.0M | 433.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | CION | AUTL |
|---|---|---|
| Price | $9.47 | $1.39 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $8.50 | $8.33 |
| AVG Volume (30 Days) | 442.0K | ★ 2.7M |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 12.70% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $244,923,000.00 | $51,128,000.00 |
| Revenue This Year | N/A | $672.42 |
| Revenue Next Year | N/A | $84.48 |
| P/E Ratio | $19.21 | ★ N/A |
| Revenue Growth | N/A | ★ 406.67 |
| 52 Week Low | $8.51 | $1.11 |
| 52 Week High | $12.71 | $2.70 |
Technical Indicators
Market Signals| Indicator | CION | AUTL |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 37.52 |
| Support Level | $9.30 | $1.34 |
| Resistance Level | $9.74 | $1.97 |
| Average True Range (ATR) | 0.23 | 0.15 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 26.90 | 5.48 |
Price Performance
Historical ComparisonAbout CION CION Investment Corporation
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
About AUTL Autolus Therapeutics plc
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.